AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis ...Middle East

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2 In both trials, the primary endpoint of clinical remission (per...

Hence then, the article about abbvie receives positive chmp opinion for risankizumab skyrizi for the treatment of adults with moderately to severely active ulcerative colitis was published today ( Friday 31/05/2024 - 09:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis )

Also on site :

• Teens arrested after large disturbance, multiple fights at Joliet mall
• Transcript: Bank of America CEO Brian Moynihan on "Face the Nation with Margaret Brennan," Dec. 28, 2025
• Feel Free customers say the kratom drink is making them sick. Toothless FDA rules on dietary supplements are helping it remain a bestseller